Walid Gellad Notes CVS' Use of ICER Metrics Wll Impact Few Drugs

September 14, 2018

"CVS has limited this threshold to very few cases so [it] will likely not have a big impact," notes CP3 Director Walid Gellad in a Biopharma Dive article about CVS' use of ICER metrics for drug pricing. The company decided in August to use value-based drug pricing analyses to determine some of the medications it will cover. A number of prominent patient groups disagree and argue that the framework does not take patient differences into account.